1
|
Fang F, Wu L, Luo X, Bu H, Huang Y, Xian Wu Y, Lu Z, Li T, Yang G, Zhao Y, Weng H, Zhao J, Ma C, Li C. Differentiation of testicular seminomas from nonseminomas based on multiphase CT radiomics combined with machine learning: A multicenter study. Eur J Radiol 2024; 175:111416. [PMID: 38460443 DOI: 10.1016/j.ejrad.2024.111416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 02/26/2024] [Accepted: 03/05/2024] [Indexed: 03/11/2024]
Abstract
BACKGROUND Differentiating seminomas from nonseminomas is crucial for formulating optimal treatment strategies for testicular germ cell tumors (TGCTs). Therefore, our study aimed to develop and validate a clinical-radiomics model for this purpose. METHODS In this study, 221 patients with TGCTs confirmed by pathology from four hospitals were enrolled and classified into training (n = 126), internal validation (n = 55) and external test (n = 40) cohorts. Radiomics features were extracted from the CT images. After feature selection, we constructed a clinical model, radiomics models and clinical-radiomics model with different machine learning algorithms. The top-performing model was chosen utilizing receiver operating characteristic (ROC) curve analysis. Decision curve analysis (DCA) was also conducted to assess its practical utility. RESULTS Compared with those of the clinical and radiomics models, the clinical-radiomics model demonstrated the highest discriminatory ability, with AUCs of 0.918 (95 % CI: 0.870 - 0.966), 0.909 (95 % CI: 0.829 - 0.988) and 0.839 (95 % CI: 0.709 - 0.968) in the training, validation and test cohorts, respectively. Moreover, DCA confirmed that the combined model had a greater net benefit in predicting seminomas and nonseminomas. CONCLUSION The clinical-radiomics model serves as a potential tool for noninvasive differentiation between testicular seminomas and nonseminomas, offering valuable guidance for clinical treatment.
Collapse
Affiliation(s)
- Fuxiang Fang
- Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Linfeng Wu
- Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Xing Luo
- Department of Urology, Baise People's Hospital, Baise 533099, China.
| | - Huiping Bu
- Department of Radiology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Yueting Huang
- Department of Epidemiology and Health Statistics, School of Public Health of Guangxi Medical University, Nanning 530021, China.
| | - Yong Xian Wu
- Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Zheng Lu
- Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Tianyu Li
- Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Guanglin Yang
- Department of Urology, Affiliated Cancer Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Yutong Zhao
- Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Hongchao Weng
- Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Jiawen Zhao
- Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Chenjun Ma
- Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| | - Chengyang Li
- Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
| |
Collapse
|
2
|
Yamashita M, Sakai T, Yamashita S, Fujishima F, Goto T, Sato T, Kawasaki Y, Kawamorita N, Tanaka T, Ito A. A case of testicular cancer with retroperitoneal lymph node metastasis of teratoma with somatic-type malignancy 18 years after initial treatment. IJU Case Rep 2023; 6:226-229. [PMID: 37405035 PMCID: PMC10315248 DOI: 10.1002/iju5.12593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Accepted: 04/11/2023] [Indexed: 07/06/2023] Open
Abstract
Introduction In testicular cancer, late relapse of teratoma with somatic-type malignancy is rare and associated with a poor survival. A case of retroperitoneal lymph node metastasis of teratoma with somatic-type malignancy 18 years after initial treatment for testicular cancer is reported. Case presentation A 46-year-old man had a 15-mm-sized mass in the para-aortic region 18 years after initial treatment for testicular cancer, without elevated serum alfa-fetoprotein or human chorionic gonadotropin levels. Laparoscopic retroperitoneal lymph node dissection was performed. The pathological findings showed teratoma with somatic-type malignancy, and the findings of primary testicular cancer reported a yolk sac tumor, not teratoma. Conclusion Late relapse of teratoma with somatic-type malignancy was resected by laparoscopic retroperitoneal lymph node dissection. Therefore, long-term follow-up should be considered if patients with small retroperitoneal masses did not undergo retroperitoneal lymph node dissection, and early detection and surgical resection for relapse might be effective.
Collapse
Affiliation(s)
- Maiko Yamashita
- Department of UrologyTohoku University Graduate School of MedicineSendaiMiyagiJapan
| | - Takanari Sakai
- Department of UrologyTohoku University Graduate School of MedicineSendaiMiyagiJapan
- Department of UrologyHachinohe City HospitalHachinoheAomoriJapan
| | - Shinichi Yamashita
- Department of UrologyTohoku University Graduate School of MedicineSendaiMiyagiJapan
| | | | - Takuro Goto
- Department of UrologyTohoku University Graduate School of MedicineSendaiMiyagiJapan
| | - Takuma Sato
- Department of UrologyTohoku University Graduate School of MedicineSendaiMiyagiJapan
| | - Yoshihide Kawasaki
- Department of UrologyTohoku University Graduate School of MedicineSendaiMiyagiJapan
| | - Naoki Kawamorita
- Department of UrologyTohoku University Graduate School of MedicineSendaiMiyagiJapan
| | - Takaki Tanaka
- Department of UrologyTohoku University Graduate School of MedicineSendaiMiyagiJapan
- Department of UrologyHachinohe City HospitalHachinoheAomoriJapan
| | - Akihiro Ito
- Department of UrologyTohoku University Graduate School of MedicineSendaiMiyagiJapan
| |
Collapse
|
3
|
Dieckmann KP, Ruf CG, Gübitz R, Wülfing C, Zengerling F. [Follow-up of testicular germ cell tumors-historical aspects and current recommendations]. Urologe A 2022; 61:484-494. [PMID: 35384479 DOI: 10.1007/s00120-022-01815-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/08/2022] [Indexed: 11/28/2022]
Abstract
Systematic follow-up examinations of patients cured of testicular cancer first gained attention by caregivers in the 1980s only after the management of the disease had significantly been improved by the introduction of cisplatin-based chemotherapy and almost synchronously, by the implementation of computerized tomography (CT) and serum tumor markers. Follow-up involves three aims: early diagnosis of recurrence, detection of treatment-related toxicity, and detection of secondary diseases. As the clinical presentation of testicular cancer is very heterogeneous, there is no uniform follow-up for the disease. Instead, risk-adapted follow-up schedules are required. Since the release of the German AWMF S3 guideline for the management of testicular cancer in 2019, high level evidence has accumulated for the noninferiority of magnetic resonance imaging (MRI) to CT with regard to abdominal imaging. Therefore, it is appropriate to modify the recommendations for follow-up given in the 2019 issue of the S3 guidelines. The modifications recommended herein relate to three issues: (1) Only three risk groups (instead of formerly four) are identified, i.e., seminoma (all stages); nonseminoma clinical stage 1b (i.e., pT2, with lymphovascular invasion) on surveillance; nonseminoma all other stages. All patients cured from poor risk disease or from relapses require individual follow-up schedules not included in the recommendations tabulated herein. (2) CT and abdominal sonography are replaced by MRI. (3) Chest X‑ray imaging during follow-up of seminoma patients is no longer recommended.
Collapse
Affiliation(s)
- Klaus-Peter Dieckmann
- Urologische Abteilung, Hodentumorzentrum, Asklepios Klinik Altona, Paul Ehrlich Straße 1, 22763, Hamburg, Deutschland.
| | | | - Raphael Gübitz
- Institut für Radiologie und Neuroradiologie, Asklepios Klinik Altona, Hamburg, Deutschland
| | - Christian Wülfing
- Urologische Abteilung, Hodentumorzentrum, Asklepios Klinik Altona, Paul Ehrlich Straße 1, 22763, Hamburg, Deutschland
| | | |
Collapse
|